Drug Profile
Research programme: anti-inflammatory therapeutics - Pulmagen Therapeutics
Alternative Names: ADC 3277; CHI 25243Latest Information Update: 23 Feb 2023
Price :
$50
*
At a glance
- Originator Pulmagen Therapeutics
- Class Anti-inflammatories; Antiasthmatics; Antifibrotics
- Mechanism of Action Peroxisome proliferator-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 23 Feb 2023 Research programme is still in preclinical development for Acute asthma in United Kingdom (Pulmagen therapeutics pipeline, February 2023)
- 23 Feb 2023 Research programme is still in preclinical development for Chronic obstructive pulmonary disease in United Kingdom (Forbion website, February 2023)
- 23 Feb 2023 Research programme is still in preclinical development for Cystic fibrosis in United Kingdom (Pulmagen therapeutics pipeline, February 2023)